On Feb. 13, the U.S. Food and Drug Administration (FDA) expanded the approved use of Imbruvica (ibrutinib) for chronic lymphocytic leukemia patients who have received at least one previous therapy.
Read more.

FDA approves Imbruvica to treat chronic lymphocytic leukemia
Share